On July 24, 2020, President Trump signed Executive Order 13947, which directed federal agencies to pursue several mechanisms for reducing prescription drug costs and increasing price transparency. The order instructed the Department of Health and Human Services to permit states to import prescription drugs from Canada, authorized Medicare to negotiate drug prices directly with manufacturers, and required pharmaceutical companies to disclose prices in direct-to-consumer advertising. While these provisions appeared to address concerns about drug affordability across the political spectrum, their actual implementation during the Trump administration remained limited due to legal obstacles and bureaucratic delays.

The executive order's intended beneficiaries included millions of Americans struggling with prescription drug costs, particularly Medicare beneficiaries and residents of states considering import programs. However, the concrete impact was substantially constrained. Importation provisions faced immediate legal challenges from pharmaceutical manufacturers, and the direct negotiation authority for Medicare did not materialize during Trump's tenure. The advertising disclosure requirement encountered industry resistance and regulatory complexity. Patients seeking relief from high drug costs during this period saw minimal concrete savings from these directives.

This action must be contextualized within a broader pattern of Trump administration healthcare policies that produced inconsistent results regarding consumer access and public health. While Executive Order 13947 ostensibly aimed at market transparency and cost reduction, simultaneous administration actions undermined public health protections. The authorization of fruit-flavored vapes, the restriction of mifepristone telehealth access, and the deprioritization of vaccines through CDC guideline changes revealed a healthcare approach prioritizing deregulation and industry flexibility over systematic consumer protection. The Title X program's shift away from birth control provision further illustrated how the administration reoriented federally-funded health services away from certain care categories.

The executive order's provisions faced significant legal challenges from pharmaceutical manufacturers who argued that price negotiation and drug importation exceeded executive authority and violated patent protections. Court cases delayed implementation throughout 2020 and beyond. Some provisions never took effect during the Trump administration, leaving the executive order functionally incomplete despite its ambitious framing. A comprehensive remedy would require both legislative action to clarify Medicare's negotiating authority and judicial resolution of constitutional questions surrounding drug importation policies.